어냅티스바이오(ANAB)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $55.20 (+0.25%), 시가총액 $2.02B, 52주 범위 $19.40 ~ $70.22.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor…
어냅티스바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
어냅티스바이오의 현재 주가는 $55.20 (+0.25%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
어냅티스바이오의 시가총액은 약 $2.02B입니다.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.